Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Neurocrine Medical Information Call Center
- Phone Number: 877-641-3461
- Email: medinfo@neurocrine.com
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- Neurocrine Clinical Site
-
Rogers, Arkansas, United States, 72758
- Neurocrine Clinical Site
-
-
California
-
Lemon Grove, California, United States, 91945
- Neurocrine Clinical Site
-
Pico Rivera, California, United States, 90660
- Neurocrine Clinical Site
-
San Diego, California, United States, 92123
- Neurocrine Clinical Site
-
Torrance, California, United States, 90502
- Neurocrine Clinical Site
-
-
Florida
-
Miami Lakes, Florida, United States, 33016
- Neurocrine Clinical Site
-
Oakland Park, Florida, United States, 33334
- Neurocrine Clinical Site
-
-
Maryland
-
Gaithersburg, Maryland, United States, 20877
- Neurocrine Clinical Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Neurocrine Clinical Site
-
-
New Jersey
-
Berlin, New Jersey, United States, 08053
- Neurocrine Clinical Site
-
-
Ohio
-
North Canton, Ohio, United States, 44720
- Neurocrine Clinical Site
-
-
Texas
-
Austin, Texas, United States, 78754
- Neurocrine Clinical Site
-
DeSoto, Texas, United States, 75115
- Neurocrine Clinical Site
-
Richardson, Texas, United States, 75080
- Neurocrine Clinical Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Completed informed consent.
- Subject has a primary diagnosis of schizophrenia.
- The subject is experiencing an acute exacerbation or relapse of symptoms and currently requires hospitalization.
- Subjects taking prohibited medications, including antipsychotics, must discontinue before study participation
- Subject is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements.
Key Exclusion Criteria:
- An unstable medical condition, chronic disease, or malignancy.
- Considered by the investigator to be at imminent risk of suicide or injury to self or others.
- Diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening.
- Positive alcohol test or drug screen for disallowed substances.
- Have a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the subject is not capable of adhering to the protocol requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose Level A
Participant administered Dose Level A (6 weeks)
|
Active treatment with orally administered NBI-1117568
|
|
Experimental: Dose Level B
Participant administered Dose Level B (6 weeks)
|
Active treatment with orally administered NBI-1117568
|
|
Experimental: Dose Level C
Participant administered Dose Level C (6 weeks)
|
Active treatment with orally administered NBI-1117568
|
|
Experimental: Dose Level D
Participant administered Dose Level D (6 weeks)
|
Active treatment with orally administered NBI-1117568
|
|
Placebo Comparator: Placebo Schedule
Participant administered placebo (6 weeks)
|
Placebo matching NBI-1117568
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score at Week 6
Time Frame: Baseline and Week 6
|
The PANSS evaluates the severity of various symptoms of schizophrenia, and is commonly used to measure symptom reduction in patients taking antipsychotics.
Each item is scored on a 7-point severity scale (1=absent; 2=minimal; 3=mild; 4=moderate; 5=moderate severe; 6=severe; 7=extreme).
The PANSS total score is derived from the summation of each item.
A higher score indicates greater severity.
|
Baseline and Week 6
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Development Lead, Neurocrine Biosciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NBI-1117568-SCZ2028
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.